

Haematologica  
HAEMATOL/2018/214635  
Version 4

Daratumumab for treatment of blastic plasmacytoid dendritic cell  
neoplasm A single-case report

Katrine F. Iversen, Paw C. Holdgaard, Birgitte Preiss, Charlotte G.  
Nyvold, and Torben Plesner

Disclosures: Conflict-of-interest disclosure Torben Plesner received research funding from Roche, Novartis, Janssen, Celgene, Abbvie and Takeda and served on advisory committees for Janssen, Celgene, Genmab, CSL Behring and Takeda.

Contributions: T.P. planned the treatment, K.F.I. followed the patient and wrote the manuscript, P.C.H. reviewed PET-CT scans, B.P. was responsible for histopathology and flow cytometry, C.G.N. revealed the mutation; and all authors critically read and approved the draft manuscript.